ZURICH (Thomson Financial) - Swiss medtech group Tecan Group AG and the Monash Antibody Technologies Facility (MATF) at Monash University, Australia, have announced a partnership to create a state-of-the-art monoclonal antibody production facility.
The new facility, which will be partly funded by the Victorian State Government, is planned to produce thousands of novel antibodies every year for researchers around the world.
Financial details were not disclosed.
The importance of monoclonal antibody production is reflected by the breadth of use, which includes research applications, diagnostic applications and successful use as therapeutic agents, Tecan said. andrew.ge.thompson@thomson.com at/lam COPYRIGHT Copyright AFX News Limited 2007. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
The new facility, which will be partly funded by the Victorian State Government, is planned to produce thousands of novel antibodies every year for researchers around the world.
Financial details were not disclosed.
The importance of monoclonal antibody production is reflected by the breadth of use, which includes research applications, diagnostic applications and successful use as therapeutic agents, Tecan said. andrew.ge.thompson@thomson.com at/lam COPYRIGHT Copyright AFX News Limited 2007. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
© 2007 AFX News
